<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Effects of Group Psychotherapy, Individual Counseling, Methylphenidate, and Placebo in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder A Randomized Clinical Trial</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2015-11-12">November 12, 2015.</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>MD</roleName><forename type="first">Alexandra</forename><surname>Philipsen</surname></persName>
							<email>alexandra.philipsen@uni-oldenburg.de</email>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Thomas</forename><surname>Jans</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Erika</forename><surname>Graf</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Swantje</forename><surname>Matthies</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Patricia</forename><surname>Borel</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Michael</forename><surname>Colla</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Laura</forename><surname>Gentschow</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Daina</forename><surname>Langner</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Christian</forename><surname>Jacob</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Silke</forename><surname>Groß-Lesch</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Esther</forename><surname>Sobanski</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Barbara</forename><surname>Alm</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Martina</forename><surname>Schumacher-Stien</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Michael</forename><surname>Roesler</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Wolfgang</forename><surname>Retz</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Petra</forename><surname>Retz-Junginger</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Bernhard</forename><surname>Kis</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Mona</forename><surname>Abdel-Hamid</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Viola</forename><surname>Heinrich</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Michael</forename><surname>Huss</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Catherine</forename><surname>Kornmann</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Arne</forename><surname>Bürger</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Evgeniy</forename><surname>Perlov</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD;</roleName><forename type="first">Gabriele</forename><surname>Ihorst</surname></persName>
						</author>
						<author>
							<persName><roleName>MBA</roleName><forename type="first">Michael</forename><surname>Schlander</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Mathias</forename><surname>Berger</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">;</forename><surname>Ludger Tebartz Van Elst</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Medical</forename><surname>Campus</surname></persName>
						</author>
						<author>
							<persName><roleName>Matthies, Borel</roleName><surname>Philipsen</surname></persName>
						</author>
						<author>
							<persName><roleName>Germany (Roesler, Retz</roleName><surname>Saar</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Paula</forename><surname>Kunze</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Markus</forename><surname>Krämer</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Jennifer</forename><surname>Uekermann</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Marc</forename><surname>Loewer</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Imke</forename><surname>Jansen</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Steffi</forename><surname>Bonfico</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Manuel</forename><surname>Jooßens</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Chiharu</forename><surname>Sadohara</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Manfred</forename><surname>Weber</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Melanie</forename><surname>Kamp</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tatja</forename><surname>Dopatka</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Harald</forename><surname>Richter</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Konstanze</forename><surname>Roemer</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Birgit</forename><surname>Leipnitz</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Sabine</forename><surname>Doyran</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Monika</forename><surname>Schulte-Altedorneburg</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Christine</forename><surname>Carl</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Clemens</forename><surname>Keutler</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Galina</forename><surname>Chervenkova</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Patricia</forename><surname>Meinhardt</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Simon</forename><surname>Bukow</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Sotiria</forename><surname>Argiriou-Martin</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Monika</forename><surname>Heine</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Andrea</forename><surname>Boreatti-Hümmer</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Julia</forename><surname>Heupel</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Susanne</forename><surname>Reichert</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Sabine</forename><surname>Müller</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Susanne</forename><surname>Kreiker</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Alexandra</forename><surname>Gessner</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Annette</forename><surname>Conzelmann</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Christina</forename><surname>Bähne</surname></persName>
						</author>
						<author>
							<persName><roleName>director</roleName><forename type="first">Rainer</forename><surname>Bredenkamp</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Helmut</forename><surname>Remschmidt</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><surname>Wassmer</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Norbert</forename><surname>Wodarz</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">School of Medicine and Health Sciences</orgName>
								<orgName type="institution">University of Oldenburg</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="institution">Psychiatry and Psychotherapy-University Hospital</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="institution">Karl-Jaspers-Klinik</orgName>
								<address>
									<postCode>D-26111</postCode>
									<settlement>Oldenburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="department">Treatment Efficacy for Adult Attention-Deficit/Hyperactivity Disorder Original Investigation Research</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">School of Medicine and Health Sciences</orgName>
								<orgName type="department" key="dep2">Department of Psychiatry and Psychotherapy</orgName>
								<orgName type="institution" key="instit1">Medical Campus University of Oldenburg</orgName>
								<orgName type="institution" key="instit2">Psychiatry and Psychotherapy-University Hospital</orgName>
								<orgName type="institution" key="instit3">Karl-Jaspers-Klinik</orgName>
								<address>
									<settlement>Bad Zwischenahn, Germany (Philipsen)</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="institution">University Medical Center Freiburg</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff6">
								<orgName type="institution">University of Freiburg</orgName>
								<address>
									<settlement>Freiburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="department">Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy</orgName>
								<orgName type="institution">van Elst)</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<orgName type="laboratory">Clinical Trials Unit</orgName>
								<orgName type="institution">University Hospital of Würzburg</orgName>
								<address>
									<settlement>Würzburg</settlement>
									<country>Germany (Jans</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff9">
								<orgName type="department">Department of Psychiatry and Psychotherapy</orgName>
								<orgName type="institution" key="instit1">University Medical Center</orgName>
								<orgName type="institution" key="instit2">University of Freiburg</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
									<settlement>Freiburg, Germany (Graf, Ihorst)</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff10">
								<orgName type="institution">Charité-University Medicine Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff11">
								<orgName type="department" key="dep1">Clinical Research Center</orgName>
								<orgName type="department" key="dep2">Max Delbrück Center for Molecular Medicine</orgName>
								<orgName type="institution">Charité-Campus Berlin-Buch</orgName>
								<address>
									<addrLine>Langner)</addrLine>
									<settlement>Berlin, Germany, Gentschow</settlement>
									<region>Colla</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff12">
								<orgName type="department">Department of Psychiatry, Psychosomatics and Psychotherapy</orgName>
								<orgName type="institution">University Hospital of Würzburg</orgName>
								<address>
									<settlement>Würzburg, Germany (Jacob</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff13">
								<orgName type="department">Department of Psychiatry and Psychotherapy</orgName>
								<orgName type="institution">Groß-Lesch)</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff14">
								<orgName type="department">Clinical Faculty Mannheim</orgName>
								<orgName type="institution" key="instit1">Central Institute of Mental Health</orgName>
								<orgName type="institution" key="instit2">University of Heidelberg</orgName>
								<address>
									<addrLine>Schumacher-Stien)</addrLine>
									<settlement>Mannheim, Germany (Sobanski, Alm</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff15">
								<orgName type="department" key="dep1">Institute for Forensic Psychology and Psychiatry</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="institution">Saarland University</orgName>
								<address>
									<settlement>Homburg</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff16">
								<orgName type="department">Department of Psychiatry and Psychotherapy</orgName>
								<orgName type="institution">Retz-Junginger)</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff17">
								<orgName type="department">Department of Psychiatry and Psychotherapy</orgName>
								<orgName type="institution">University Medical Center Mainz</orgName>
								<address>
									<settlement>Mainz</settlement>
									<country>Germany (Retz</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff18">
								<orgName type="department">Department of Psychiatry and Psychotherapy</orgName>
								<orgName type="institution">University Medical Center Göttingen</orgName>
								<address>
									<settlement>Göttingen</settlement>
									<country>Germany (Kis</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff19">
								<orgName type="department" key="dep1">Faculty of Medicine</orgName>
								<orgName type="department" key="dep2">Duisburg and Essen</orgName>
								<orgName type="department" key="dep3">Department of Child and Adolescent Psychiatry and Psychotherapy</orgName>
								<orgName type="institution" key="instit1">LVR-Hospital Essen</orgName>
								<orgName type="institution" key="instit2">University of Duisburg-Essen</orgName>
								<orgName type="institution" key="instit3">Germany (Abdel-Hamid, Heinrich)</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff20">
								<orgName type="department">Institute for Innovation and Valuation in Health Care</orgName>
								<orgName type="institution">University Medicine Mainz</orgName>
								<address>
									<addrLine>Bürger)</addrLine>
									<settlement>Mainz, Germany (Huss, Kornmann, Wiesbaden</settlement>
									<country>Germany (Schlander</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff21">
								<orgName type="department">Department of Psychiatry and Psychotherapy</orgName>
								<orgName type="institution">Charité-University Medicine Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff22">
								<orgName type="department" key="dep1">Department of Psychiatry and Psychotherapy</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="department" key="dep3">Duisburg and Essen</orgName>
								<orgName type="institution" key="instit1">LVR-Hospital Essen</orgName>
								<orgName type="institution" key="instit2">University of Duisburg-Essen</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff23">
								<orgName type="department">Department of Psychiatry and Psychotherapy</orgName>
								<orgName type="institution" key="instit1">University Medical Center Freiburg</orgName>
								<orgName type="institution" key="instit2">University of Freiburg</orgName>
								<address>
									<settlement>Freiburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff24">
								<orgName type="department">Institute for Forensic Psychology and Psychiatry</orgName>
								<orgName type="institution">Saarland University Medical Center</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff25">
								<orgName type="department">Faculty of Medicine</orgName>
								<orgName type="institution">Saarland University</orgName>
								<address>
									<settlement>Homburg, Saar</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff26">
								<orgName type="department">Department of Child and Adolescent Psychiatry and Psychotherapy</orgName>
								<orgName type="institution">St Elisabethen Krankenhaus</orgName>
								<address>
									<settlement>Lörrach</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff27">
								<orgName type="institution">Michael Huss</orgName>
								<address>
									<region>MD</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff28">
								<orgName type="department">Department of Child and Adolescent Psychiatry and Psychotherapy</orgName>
								<orgName type="institution">University Medicine Mainz</orgName>
								<address>
									<settlement>Mainz</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff29">
								<orgName type="department" key="dep1">Department of Psychiatry and Psychotherapy</orgName>
								<orgName type="department" key="dep2">Clinical Faculty Mannheim</orgName>
								<orgName type="institution" key="instit1">Central Institute of Mental Health</orgName>
								<orgName type="institution" key="instit2">University of Heidelberg</orgName>
								<address>
									<settlement>Mannheim</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff30">
								<orgName type="department">Department of Psychiatry, Psychosomatics and Psychotherapy and Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy</orgName>
								<orgName type="institution">University Hospital of Würzburg</orgName>
								<address>
									<settlement>Würzburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff31">
								<orgName type="laboratory">Clinical Trials Unit</orgName>
								<orgName type="institution" key="instit1">University Medical Center</orgName>
								<orgName type="institution" key="instit2">University of Freiburg</orgName>
								<address>
									<settlement>Freiburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff32">
								<orgName type="department">Department of Child and Adolescent Psychiatry</orgName>
								<orgName type="institution">Philipps University</orgName>
								<address>
									<settlement>Marburg</settlement>
									<country>Germany; Gernot</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff33">
								<orgName type="department">Institute for Medical Statistics, Informatics, and Epidemiology</orgName>
								<orgName type="institution">University of Cologne</orgName>
								<address>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff34">
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">University of Regensburg</orgName>
								<address>
									<settlement>Regensburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff35">
								<orgName type="department">12 . Castells X</orgName>
								<orgName type="institution">Ramos-Quiroga JA</orgName>
								<address>
									<settlement>Rigau D, et al</settlement>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Effects of Group Psychotherapy, Individual Counseling, Methylphenidate, and Placebo in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder A Randomized Clinical Trial</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2015-11-12">November 12, 2015.</date>
						</imprint>
					</monogr>
					<idno type="MD5">5ED25B5FC33F4F10BE115F3A6EF1EC6D</idno>
					<idno type="DOI">10.1001/jamapsychiatry.2015.2146</idno>
					<note type="submission">Received GPT as randomized 7 Did not receive GPT as randomized 3 PW 3 ICWD 1 Other 101 Received methylphenidate as randomized 6 Did not receive methylphenidate as randomized 1 PW 2 ICWD 2 Other 1 Unknown T0 109 Randomized to GPT and placebo 105 Received GPT as randomized 4 Did not receive GPT as randomized 1 PW 1 ICWD 2 Other 105 Received placebo as randomized 4 Did not receive placebo as randomized 1 PW 1 ICWD 2 Other T0 Randomized to CM and placebo 103 Received CM as randomized 4 Did not receive CM as randomized 1 GPT 1 PW 2 ICWD 104 Received placebo as randomized 3 Did not receive placebo as randomized 1 PW 1 ICWD 1 Other T0 110 Randomized to CM and methylphenidate 106 Received CM as randomized 4 Did not receive CM as randomized 2 PW 1 ICWD 1 Unknown 104 Received methylphenidate as randomized 6 Did not receive methylphenidate as randomized 3 PW 1 ICWD 1 Other 1 Unknown Submitted for Publication: April 17, 2015; final revision received August 17, 2015; accepted August 18, 2015.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:26+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>for the Comparison of Methylphenidate and Psychotherapy in Adult ADHD Study (COMPAS) Consortium IMPORTANCE Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder with high prevalence in adulthood.</s><s>There is a recognized need to assess the efficacy of psychotherapy in adult ADHD.</s><s>OBJECTIVE To evaluate the efficacy of cognitive behavioral group psychotherapy (GPT) compared with individual clinical management (CM) and that of methylphenidate hydrochloride compared with placebo.</s><s>DESIGN, SETTING, AND PARTICIPANTS Prospective, multicenter, randomized clinical trial of 18to 58-year-old outpatients with ADHD from 7 German study centers.</s><s>Patients were recruited between January 2007 and August 2010, treatment was finalized in August 2011, and final follow-up assessments occurred in March 2013.</s></p><p><s>INTERVENTIONS Sessions of GPT and CM were held weekly for the first 12 weeks and monthly thereafter (9 months).</s><s>Patients received either methylphenidate or placebo for 1 year.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MAIN OUTCOMES AND MEASURES</head><p><s>The primary outcome was the change in the ADHD Index of the Conners Adult ADHD Rating Scale from baseline to the end of the 3-month intensive treatment (blinded observer ratings).</s><s>Secondary outcomes included ADHD ratings after 1 year, blinded observer ratings using the Clinical Global Impression Scale, and self-ratings of depression.</s><s>RESULTS Among 1480 prescreened patients, 518 were assessed for eligibility, 433 were centrally randomized, and 419 were analyzed as randomized.</s><s>After 3 months, the ADHD Index all-group baseline mean of 20.6 improved to adjusted means of 17.6 for GPT and 16.5 for CM, with no significant difference between groups.</s><s>Methylphenidate (adjusted mean, 16.2) was superior to placebo (adjusted mean, 17.9) (difference, −1.7; 97.5% CI, −3.0 to −0.4; P = .003).</s><s>After 1 year, treatment effects remained essentially stable.</s><s>Descriptive analyses showed that methylphenidate was superior to placebo in patients assigned to GPT (difference, −1.7; 95% CI, −3.2 to −0.1; P = .04)</s><s>or CM (difference, −1.7; 95% CI, −3.3 to −0.2; P = .03).</s><s>Regarding depression, no significant differences were found.</s><s>In contrast, GPT was superior to CM for all visits in the Clinical Global Impression global assessment of effectiveness.</s></p><p><s>CONCLUSION AND RELEVANCE Highly structured group intervention did not outperform individual CM with regard to the primary outcome.</s><s>Psychological interventions resulted in better outcomes during a 1-year period when combined with methylphenidate as compared with placebo.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Design and Participants</head><p><s>All methodological issues have been described in detail. <ref type="bibr" target="#b18">21,</ref><ref type="bibr" target="#b27">30</ref></s><s>he Comparison of Methylphenidate and Psychotherapy in Adult ADHD Study (COMPAS) was a factorial, multicenter, randomized clinical trial comparing GPT with CM and methylphenidate with placebo.</s><s>The full trial protocol appears in Supplement 1. Inclusion and exclusion criteria are listed in eAppendix 1 in Supplement 2. The diagnosis of ADHD, according to DSM-IV and other psychiatric symptoms, was established by psychiatric expert assessment and validated using observer rating scales and self-rating scales, including the Wender Utah Rating Scale (WURS-k; in German), <ref type="bibr" target="#b28">31,</ref><ref type="bibr" target="#b30">32</ref> the ADHD diagnostic checklist (ADHD-DC; in German), <ref type="bibr" target="#b32">33</ref> and the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) and Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II) (in German). <ref type="bibr" target="#b34">34,</ref><ref type="bibr">35</ref></s><s>Concurrent use of psychopharmacologic or psychotherapeutic treatments was not allowed outside the trial.</s><s>The study received ethics committee approval from University of Freiburg.</s><s>Written informed consent was obtained from all participants.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Randomization and Masking</head><p><s>Eligible patients were randomized in batches of 14 or 15 at a time (1 × 12, 1 × 16).</s><s>The randomization allowed for GPT in groups of 6 to 9 patients.</s><s>Either GPT or CM plus a medication number (used to allocate either methylphenidate or placebo) was centrally assigned. <ref type="bibr" target="#b18">21,</ref><ref type="bibr" target="#b27">30</ref></s><s>Treatments were allocated in a 1:1:1:1 ratio, stratified in blocks of 4 within the center (block size was kept confidential to help ensure concealment; the protocol stated that it was variable).</s><s>Blocks were sequentially combined for application to patient batches.</s><s>For patients and therapists, the study was blinded for medication and open for assignment to GPT or CM.</s><s>Observers rating ADHD symptoms (ADHD-DC, Conners Adult ADHD Rating Scale [CAARS] long German version, <ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref> and CGI) were blinded to treatment allocation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Procedures</head><p><s>Following randomization and baseline assessment, participants received methylphenidate hydrochloride (sustained release; initial dosage of 10 mg/d; titration with 10 mg/wk over 6 weeks up to 60 mg/d; individual dosage to a maximum daily dosage of 1.3 mg/kg of body weight) or placebo.</s><s>Medication adherence was assessed by pill count.</s></p><p><s>The GPT sessions followed a validated manual (eAppendix 2 in Supplement 2). <ref type="bibr">40,</ref><ref type="bibr" target="#b39">41</ref></s><s>Individual CM was the active, nonpharmacological control condition chosen to simulate general practice.</s><s>The CM participants received nonspecific counseling in individual sessions (15-20 minutes) (eAppendix 2 in Supplement 2). <ref type="bibr" target="#b18">21,</ref><ref type="bibr" target="#b27">30</ref></s><s>Twelve weekly sessions of GPT and CM were followed by 10 monthly sessions over 52 weeks. <ref type="bibr" target="#b18">21,</ref><ref type="bibr" target="#b27">30</ref></s><s>The CM sessions were audio recorded and the GPT sessions were video recorded to assess treatment fidelity by 3 blinded, independent, expert raters. <ref type="bibr" target="#b18">21,</ref><ref type="bibr" target="#b27">30</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Outcome Measures</head><p><s>Visits for assessing primary and secondary end points took place after randomization (baseline, or time 1 [T1]), after 12 weeks of intensive treatment (T2), during maintenance after 24 weeks (T3), at the end of treatment (week 52; T4), and at 2.5 years after T1 (follow-up; T5).</s><s>The primary outcome was the change in the observer-rated CAARS ADHD Index from T1 to T2.</s><s>Secondary outcome measures included other CAARS subscales, the ADHD-DC, the Beck Depression Inventory, <ref type="bibr" target="#b40">42,</ref><ref type="bibr" target="#b41">43</ref> and CGI subscales; we report results for these end points at T2 and T4.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sample Size Estimation</head><p><s>The sample size was derived assuming an effect size (ES) of 0.33 for the 2 primary 2 × 2 comparisons (GPT or methylpheni-date vs control conditions <ref type="bibr" target="#b18">21,</ref><ref type="bibr" target="#b27">30</ref> ).</s><s>To achieve a power of 80% for a t test at a 2-sided α of 2.5% to adjust for multiplicity, 350 patients were needed.</s><s>A target of 448 randomizations was  planned to compensate for dropouts.</s><s>After a recruitment delay, a power of 78% (430 patients) was deemed acceptable to the study team, and no more patients were enrolled.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Analysis</head><p><s>Primary End Point Changes in the CAARS ADHD Index from T1 to T2 were analyzed by randomized treatment in the full analysis set.</s><s>To model a stable postdropout response, missing postbaseline data were replaced using multiple imputation through last mean carried forward (LMCF) <ref type="bibr" target="#b42">44</ref> in an analysis of covariance linear model, using time, treatments, center, and baseline measurements as fixed covariates (eAppendix 3 in Supplement 2).</s><s>Adjusted means per treatment were calculated from this.</s><s>For the primary treatment comparisons at T2, an additional interaction term (GPT × MPH; kept if significant at 10%) was pretested.</s></p><p><s>The 2 primary comparisons were reported with confirmatory 97.5% confidence intervals (corrected for multiple testing of GPT vs CM and methylphenidate vs placebo) and descriptive 95% confidence intervals.</s><s>These were statistically significant if P &lt; .025</s><s>(P &lt; .05</s><s>for other comparisons).</s><s>If a primary treatment comparison was statistically significant, a confirmatory closed-test procedure sequentially compared GPT with methylphenidate vs CM with methylphenidate; GPT with methylphenidate vs GPT with placebo; CM with methylphenidate vs CM with placebo; and GPT with methylphenidate vs CM with placebo (descriptive reporting with nominal P values after the first nonsignificant result <ref type="bibr" target="#b18">21,</ref><ref type="bibr" target="#b27">30</ref> ).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Secondary End Points</head><p><s>Responses were defined as decreases in the observer rating variant of the CAARS ADHD Index of 30% or more.</s><s>To calculate response rates, we analyzed only complete cases and used logistic regression.</s><s>Other rating scales (other CAARS subscales, ADHD-DC, and Beck Depression Inventory) were evaluated using LMCF.</s><s>Complete cases of CGI subscales (ordinal data) were analyzed in a proportional odds model.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety</head><p><s>Adverse events (AEs) were evaluated according to received treatment in safety set 1 (patients who attended ≥1 GPT or CM session) and safety set 2 (patients who received ≥1 dose of methylphenidate or placebo).</s></p><p><s>All analyses were prespecified and performed using SAS version 9.2 statistical software (SAS Institute, Inc).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Effect Sizes</head><p><s>Descriptive pre-post ESs were calculated using LMCF means and square roots of the residual variance, averaged over LMCF imputations as standard deviation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Interim Analysis</head><p><s>An interim report on recruitment, compliance, and safety (no efficacy data) was presented to the independent data monitoring committee in April 2010, based on data up to T3 for the 231 patients randomized as of May 2009.</s><s>The independent data monitoring committee recommended continuing the trial without modifications.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sample</head><p><s>Figure <ref type="figure" target="#fig_0">1</ref> illustrates patient flow. <ref type="bibr" target="#b27">30</ref></s><s>Patients were recruited between January 2007 and August 2010, with randomization between April 10, 2007, and August 18, 2010.</s><s>Treatment was finalized in August 2011, and final follow-up assessments occurred in March 2013 (data not reported here).</s><s>In sum, 1480 patients were contacted.</s><s>In 962 prescreened patients (65.0%), no standardized assessment for eligibility was carried out owing to lack of interest or inability to meet time requirements (391 of 962 [40.6%]) or contraindications against methylphenidate (194 of 962 [20.2%]).</s><s>The remaining 518 patients were assessed for eligibility; 85 were excluded, primarily for refusing further participation (47 of 85 [55.3%]). <ref type="bibr" target="#b26">29</ref></s><s>f the 433 randomized individuals, 107 were randomized to GPT with methylphenidate, 109 to GPT with placebo, 110 to CM with methylphenidate, and 107 to CM with placebo.</s><s>Table <ref type="table" target="#tab_1">1</ref> summarizes the sociodemographic and clinical characteristics at baseline.</s></p><p><s>We obtained baseline ratings in 419 of the 433 randomized participants; these constituted the full analysis set for the primary LMCF efficacy analysis.</s><s>Only one-third of the patients (138 of 419 [</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Primary End Point at T2</head><p><s>The test for GPT × methylphenidate interaction was nonsignificant (P = .95).</s><s>Therefore, a 2 × 2 approach (vs a 4-arm approach) was applied evaluating GPT vs CM and methylphenidate vs placebo.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Confirmatory 2-Arm Comparisons</head><p><s>The study detected no advantage for the decline in ADHD symptoms for GPT vs CM (Table <ref type="table" target="#tab_3">2</ref>, Table <ref type="table" target="#tab_4">3</ref>, and Figure <ref type="figure">2</ref>).</s><s>The ADHD Index scores improved from the all-group baseline mean of 20.6 to an adjusted mean of 17.6 at T2 for GPT (n = 209; ES = −0.55)</s><s>and 16.5 for CM (n = 210; ES = −0.75)</s><s>(Table <ref type="table" target="#tab_3">2</ref>  Figure <ref type="figure">2</ref>).</s><s>The difference between GPT and CM was nonsignificant (ADHD Index score difference for GPT vs CM, 1.1; 97.5% CI, −0.2 to 2.4; 95% CI, 0.0 to 2.2; P = .06).</s><s>Symptoms decreased considerably more in patients assigned to methylphenidate (n = 210; adjusted mean ADHD Index score, 16.2; ES = −0.81)</s><s>vs placebo (n = 209; adjusted mean ADHD Index score, 17.9; ES = −0.50)</s><s>(Table <ref type="table" target="#tab_3">2</ref> and Figure <ref type="figure">2</ref>).</s><s>This difference proved significant (ADHD Index score difference for methylphenidate vs placebo, -1.7; 97.5% CI, −3.0 to −0.4; 95% CI, −2.8 to −0.6; P = .003).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Confirmatory 4-Arm Comparisons</head><p><s>Because the difference between methylphenidate and placebo proved significant, we applied sequential 4-arm analyses.</s><s>In patients randomized to methylphenidate, GPT vs CM produced nonsignificant findings (ADHD Index score difference, 1.1; 95% CI, −0.4 to 2.7; P = .16).</s><s>Thus, confirmatory statistical testing was terminated.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Further Descriptive Analyses</head><p><s>The following preplanned exploratory comparisons were conducted.</s><s>Comparing methylphenidate with placebo in patients assigned to GPT showed that methylphenidate was superior to placebo (ADHD Index score difference, −1.7; 95% CI, −3.2 to −0.1; P = .04).</s><s>This superiority was also evident in patients randomized to CM (ADHD Index score difference for methylphenidate vs placebo, −1.7; 95% CI, −3.3 to −0.2; P = .03).</s><s>In contrast, comparing both interventions (GPT and methylphenidate) with the control treatments produced a nonsignificant benefit (ADHD Index score difference for GTP with methylphenidate vs CM with placebo,−0.6;</s><s>95% CI, −2.2 to 0.9; P = .43).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Secondary Outcomes</head><p><s>Long-term ADHD Index At T3 and T4, the treatment effects of GPT vs CM and methylphenidate vs placebo remained stable (Table <ref type="table" target="#tab_3">2</ref> and Figure <ref type="figure">2</ref>).</s><s>The slight disadvantage of GPT vs CM at T2 and T3 became a slight nonsignificant benefit at T4.</s><s>In contrast, methylphenidate was significantly better than placebo during the entire study period.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Response</head><p><s>At T2, responses were highest in the CM with methylphenidate arm at 47.4%, compared with 32.5% in CM with placebo, 29.7% in GPT with methylphenidate, and 24.4% in GPT with placebo (GPT vs CM, P = .009;</s><s>methylphenidate vs placebo, P = .05).</s><s>At T4, response rates were similar in all 4 treatment arms, varying between 44.1% for GPT with placebo and 52.9% for CM with methylphenidate (GPT vs CM, P = .72;</s><s>methylphenidate vs placebo, P = .52)</s><s>(Table <ref type="table" target="#tab_4">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Other Measures of ADHD Severity</head><p><s>For the self-ratings of the ADHD Index, GPT's nonsignificant disadvantage vs CM at T2 and T3 became a nonsignificant advantage at T4. Methylphenidate proved superior to placebo at all 3 measurement times (Table <ref type="table">4</ref>).</s></p><p><s>The CAARS ratings and the ADHD-DC revealed comparable results in total and subscale scores, with no difference between GPT and CM (Table <ref type="table" target="#tab_3">2</ref>; eTable 2 in Supplement 2).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Depression</head><p><s>Regarding depression, no significant differences were found between patients treated with GPT vs CM or methylphenidate vs placebo.</s><s>Methylphenidate exhibited nonsignificantly better Beck Depression Inventory ratings at all 3 times.</s><s>More-over, GPT's nonsignificant disadvantage at T2 became a nonsignificant advantage at T4 (Table <ref type="table">4</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CGI Scores</head><p><s>Comparison of CGI severity score between GPT and CM revealed no major differences (Table <ref type="table" target="#tab_6">5</ref>).</s><s>Concerning CGI global change, GPT performed better than CM at all times; however, it was significant only at T4 (P = .047).</s><s>Methylphenidate always performed better than placebo, but this was significant only at T3 (P = .008)</s><s>(Table <ref type="table" target="#tab_6">5</ref>).</s><s>The end point CGI global assessment of effectiveness always favored GPT over CM and methylphenidate over placebo.</s><s>This difference in GPT's favor was highly significant at T4 (P &lt; .001)</s><s>(Table <ref type="table" target="#tab_6">5</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety</head><p><s>Frequencies of AEs and serious AEs are shown in eTable 3 in Supplement 2. No suicides occurred.</s><s>Two patients receiving methylphenidate became pregnant, despite contraception.</s><s>One terminated her pregnancy for psychosocial reasons; the other experienced no AEs during delivery or early development of the child.</s><s>Changes in heart rate, blood pressure, and body weight from T1 to T4 are shown in eTable 4 in Supplement 2.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>The COMPAS is the first multimodal, multicenter randomized clinical trial to examine the efficacy of nonpharmacologi-Table <ref type="table">4</ref>. Self-rated CAARS ADHD Index and Self-rated BDI at Baseline (T1), 13 Weeks (T2), 26 Weeks (T3), and 52 Weeks (T4) Based on Last Mean Carried Forward Analysis for the 419 Participants in the Full Analysis Set by Randomized Intervention, Adjusted for Baseline Measurement and Center cal treatments (GPT vs CM) in combination with methylphenidate or placebo.</s><s>We recruited a large representative sample that compares well with other trials. <ref type="bibr" target="#b43">45,</ref><ref type="bibr" target="#b44">46</ref></s><s>In contrast to our hypothesis, GPT could not be shown to be more effective than the CM control condition, except in CGI-related secondary outcomes.</s><s>Methylphenidate was superior to placebo in nearly all outcome domains.</s><s>All 4 treatment arms exhibited improvements in both symptoms and CGI ratings.</s><s>This finding contrasts with previous findings in which preliminary evidence has shown the superiority of structured disorder-oriented GP T over unspec ific group control conditions. <ref type="bibr" target="#b20">23,</ref><ref type="bibr" target="#b22">25,</ref><ref type="bibr" target="#b24">26</ref></s><s>However, our study used an individual CM control condition to simulate practice care in an optimal way.</s><s>As a consequence, the investigated group program, although found effective in earlier preliminary studies, may not have been sufficiently effective to outperform the individual control condition.</s><s>Another explanation may be that our control treatment-although performed adherent to the protocolwas not an attention placebo; instead, it included face-to-face counseling activities, which potentially responded better to the individual needs of participants than the groups.</s><s>We cannot extrapolate to specific psychotherapy methods beyond the one tested.</s></p><p><s>While CM appeared superior to specific GPT after 3 months, long-term effects after 1 year favored GPT slightly.</s><s>In particular, CGI global assessments of effectiveness of the interventions were significantly better for GPT at all measurement times.</s><s>This is remarkable because this scale represents more general measures of well-being (eg, improved acceptance, selfesteem, coping skills), which were the focus of GPT.</s></p><p><s>Confirming preliminary evidence, <ref type="bibr" target="#b25">27</ref> our trial clearly showed that combinations of GPT or CM with methylphenidate were superior to combinations with placebo.</s></p><p><s>Our study provides no evidence that methylphenidate reduces depressive symptoms.</s><s>This contrasts with some preliminary evidence, <ref type="bibr" target="#b45">47</ref> but it supports more recent research. <ref type="bibr" target="#b46">48,</ref><ref type="bibr" target="#b47">49</ref></s><s>ur results relate well to the large childhood Multimodal Treatment Study of Children With ADHD, <ref type="bibr" target="#b48">50</ref> which also found significant improvements in all treatment conditions (medication management, intensive behavioral treatment, the two combined, or standard community care).</s><s>As in our trial, medication proved to be superior to intensive behavioral therapy. <ref type="bibr" target="#b48">50</ref></s><s> nonsignificant interaction term does not exclude the possibility that the effect of GPT may depend on MPH and vice versa.</s><s>However, the 2-arm and 4-arm comparisons of GPT vs CM and GPT with methylphenidate vs CM with methylphenidate, as well as methylphenidate vs placebo and GPT with methylphenidate vs GPT with placebo, gave identical results, implying that our data do not suggest such dependencies.</s></p><p><s>Blinding was restricted to medication and to observer ratings of ADHD and CGI.</s><s>We did not systematically assess whether blinding was effective in patients.</s><s>However, because patients who received methylphenidate and those who received placebo both reported high numbers of AEs, with minimal effects to vital signs and weight, we believe the blinding was effective.</s><s>As in other studies <ref type="bibr" target="#b49">51</ref> and in line with the nature of the disorder, compliance was a challenge: more than one-third of the randomized patients dropped out.</s><s>These missing data can be viewed as a study result <ref type="bibr" target="#b49">51</ref> rather than as a shortcoming, since most dropouts occurred in the CM with placebo condition.</s><s>Because the available data (eTable 5 in Supplement 2) and the imputed LMCF analyses of the full analysis set showed similar results, we conjecture that our findings were not confounded by dropouts.</s></p><p><s>Our findings may not be generalizable to routine care settings in which comorbidities are not excluded and patients may have more psychosocial impairments or difficulties meeting the time and effort requirements for this trial.</s></p><p><s>Despite the significant superiority of methylphenidate vs placebo on most ADHD scales, the mean differences between methylphenidate vs placebo and GPT vs CM were relatively small.</s><s>Our data could not show whether superior CGI ratings of GPT reflected otherwise hidden differences in patients' daily functioning.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>The COMPAS trial sheds light on issues that, to our knowledge, have not yet been addressed.</s><s>First, it almost doubles the observation period of the longest randomized study conducted globally so far. <ref type="bibr" target="#b50">52</ref></s><s>Second, it systematically addresses the effect of medication on the outcome of psychotherapy.</s><s>Previous studies were pilot studies, <ref type="bibr" target="#b25">27</ref> not placebo controlled, <ref type="bibr" target="#b19">[22]</ref><ref type="bibr" target="#b20">[23]</ref><ref type="bibr" target="#b21">[24]</ref><ref type="bibr" target="#b22">[25]</ref><ref type="bibr" target="#b24">[26]</ref> or included medication-treated patients with persistent ADHD symptoms. <ref type="bibr" target="#b13">16,</ref><ref type="bibr" target="#b14">17,</ref><ref type="bibr" target="#b22">25</ref></s><s>Third, we compared a highly structured GPT with a less controlled CM condition, also an untested area.</s></p><p><s>To our knowledge, COMPAS is the first trial to demonstrate long-term maintenance effects of ADHD treatments under controlled conditions.</s><s>We demonstrate that psychological interventions result in better outcomes when combined with methylphenidate as compared with placebo.</s><s>Our data do not suggest that highly structured group intervention outperforms individual CM, which is much easier to implement in practical care than specifically tailored and highly structured GPT.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>Trial Design and Flow of Patients</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>T2: wk 13, primary end point 22</head><label></label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell>Discontinued study visits</cell></row><row><cell></cell><cell></cell><cell></cell><cell>15 ICWD</cell></row><row><cell></cell><cell></cell><cell></cell><cell>7 Other</cell></row><row><cell></cell><cell></cell><cell></cell><cell>19 Stopped CM</cell></row><row><cell></cell><cell></cell><cell></cell><cell>10 PW</cell></row><row><cell></cell><cell></cell><cell></cell><cell>2 AE</cell></row><row><cell></cell><cell></cell><cell></cell><cell>4 ICWD</cell></row><row><cell></cell><cell></cell><cell></cell><cell>2 Other</cell></row><row><cell></cell><cell></cell><cell></cell><cell>1 Unknown</cell></row><row><cell></cell><cell></cell><cell></cell><cell>27 Stopped placebo</cell></row><row><cell></cell><cell></cell><cell></cell><cell>16 PW</cell></row><row><cell></cell><cell></cell><cell></cell><cell>4 AE</cell></row><row><cell></cell><cell></cell><cell></cell><cell>5 ICWD</cell></row><row><cell></cell><cell></cell><cell></cell><cell>2 Other</cell></row><row><cell>T4: wk 52, end of study treatment</cell><cell>T4: wk 52, end of study treatment</cell><cell>T4: wk 52, end of study treatment</cell><cell>T4: wk 52, end of study treatment</cell></row><row><cell>24 Discontinued study visits after T2</cell><cell>35 Discontinued study visits after T2</cell><cell>28 Discontinued study visits after T2</cell><cell>Discontinued study visits after T2</cell></row><row><cell>11 ICWD</cell><cell>14 ICWD</cell><cell>12 ICWD</cell><cell>24 ICWD</cell></row><row><cell>13 Other</cell><cell>21 Other</cell><cell>16 Other</cell><cell>9 Other</cell></row><row><cell>28 Stopped GPT after T2</cell><cell>30 Stopped GPT after T2</cell><cell>29 Stopped CM after T2</cell><cell>Stopped CM after T2</cell></row><row><cell>12 PW</cell><cell>19 PW</cell><cell>19 PW</cell><cell>30 PW</cell></row><row><cell>8 Other</cell><cell>9 Other</cell><cell>5 AE</cell><cell>6 Other</cell></row><row><cell>8 Unknown</cell><cell>2 Unknown</cell><cell>5 Other</cell><cell>Stopped placebo after T2</cell></row><row><cell>23 Stopped methylphenidate after T2</cell><cell>35 Stopped placebo after T2</cell><cell>32 Stopped methylphenidate after T2</cell><cell>30 PW</cell></row><row><cell>14 PW</cell><cell>28 PW</cell><cell>20 PW</cell><cell>1 AE</cell></row><row><cell>5 AE</cell><cell>2 AE</cell><cell>10 AE</cell><cell>8 Other</cell></row><row><cell>4 Other</cell><cell>5 Other</cell><cell>1 ICWD</cell><cell></cell></row><row><cell></cell><cell></cell><cell>1 Other</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Demographic and Screening Characteristics of the 419 Participants in the Full Analysis Set by Randomized Intervention</s></p></div></figDesc><table><row><cell></cell><cell>No. (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>GPT +</cell><cell>GPT +</cell><cell>CM +</cell><cell>CM +</cell><cell></cell></row><row><cell></cell><cell>Methylphenidate</cell><cell>Placebo</cell><cell>Methylphenidate</cell><cell>Placebo</cell><cell></cell></row><row><cell>Characteristic</cell><cell>(n = 103)</cell><cell>(n = 106)</cell><cell>(n = 107)</cell><cell>(n = 103)</cell><cell></cell></row><row><cell>Age, y</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean (SD)</cell><cell>35 (10)</cell><cell>35 (11)</cell><cell>35 (10)</cell><cell>35 (10)</cell><cell></cell></row><row><cell>Range</cell><cell>18-57</cell><cell>18-58</cell><cell>18-54</cell><cell>19-56</cell><cell></cell></row><row><cell>Male</cell><cell>53 (51.5)</cell><cell>58 (54.7)</cell><cell>54 (50.5)</cell><cell>45 (43.7)</cell><cell></cell></row><row><cell>Verbal IQ</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean (SD)</cell><cell>112 (15)</cell><cell>111 (14)</cell><cell>113 (14)</cell><cell>110 (17)</cell><cell></cell></row><row><cell>Range</cell><cell>88-145</cell><cell>89-143</cell><cell>92-143</cell><cell>23-145 a</cell><cell></cell></row><row><cell>White</cell><cell>100 (97.1)</cell><cell>104 (98.1)</cell><cell>107 (100.0)</cell><cell>101 (98.1)</cell><cell></cell></row><row><cell>University entrance diploma, from year 5 to 12/13</cell><cell>44 (42.7)</cell><cell>42 (39.6)</cell><cell>58 (54.2)</cell><cell>45 (43.7)</cell><cell></cell></row><row><cell>Employment</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Full-or part-time</cell><cell>75 (72.8)</cell><cell>70 (66.0)</cell><cell>81 (75.7)</cell><cell>77 (74.8)</cell><cell></cell></row><row><cell>Unemployed b</cell><cell>16 (15.5)</cell><cell>21 (19.8)</cell><cell>13 (12.1)</cell><cell>16 (15.5)</cell><cell></cell></row><row><cell>Family life</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>≥2 Children</cell><cell>35 (34.0)</cell><cell>39 (36.8)</cell><cell>37 (34.6)</cell><cell>36 (35.0)</cell><cell></cell></row><row><cell>Single according to marital status</cell><cell>64 (62.1)</cell><cell>54 (50.9)</cell><cell>59 (55.1)</cell><cell>55 (53.4)</cell><cell></cell></row><row><cell>Living with a partner</cell><cell>41 (39.8)</cell><cell>53 (50.0)</cell><cell>46 (43.0)</cell><cell>55 (53.9) c</cell><cell></cell></row><row><cell>Previous psychopharmacological treatments</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>≥1 Previous psychopharmacological medication</cell><cell>44 (42.7)</cell><cell>53 (50.0)</cell><cell>50 (46.7)</cell><cell>53 (51.5)</cell><cell></cell></row><row><cell>Antidepressants</cell><cell>25 (24.3)</cell><cell>33 (31.1)</cell><cell>36 (33.6)</cell><cell>31 (30.1)</cell><cell></cell></row><row><cell>Methylphenidate, amphetamine, other</cell><cell>23 (22.3)</cell><cell>26 (24.5)</cell><cell>17 (15.9)</cell><cell>24 (23.3)</cell><cell></cell></row><row><cell>psychostimulants</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Sedatives, neuroleptics, atomoxetine</cell><cell>10 (9.7)</cell><cell>17 (16.0)</cell><cell>16 (15.0)</cell><cell>17 (16.5)</cell><cell></cell></row><row><cell>hydrochloride, mood stabilizers, others</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Previous psychiatric or psychotherapeutic</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>treatments</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Outpatient</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Psychiatric</cell><cell>30 (29.1)</cell><cell>38 (35.8)</cell><cell>36 (33.6)</cell><cell>44 (42.7)</cell><cell></cell></row><row><cell>Psychotherapeutic</cell><cell>61 (59.2)</cell><cell>57 (53.8)</cell><cell>55 (51.4)</cell><cell>50 (48.5)</cell><cell></cell></row><row><cell>Psychiatric or psychotherapeutic</cell><cell>72 (69.9)</cell><cell>72 (67.9)</cell><cell>69 (64.5)</cell><cell>68 (66.0)</cell><cell></cell></row><row><cell>Inpatient</cell><cell>23 (22.3)</cell><cell>18 (17.0)</cell><cell>22 (20.6)</cell><cell>20 (19.4)</cell><cell></cell></row><row><cell>WURS-k score, mean (SD)</cell><cell>40.6 (9.1)</cell><cell cols="2">41.4 (10.7) 42.1 (10.4)</cell><cell>42.2 (10.3)</cell><cell></cell></row><row><cell>ADHD subtype</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Combined</cell><cell>65 (63.1)</cell><cell>54 (50.9)</cell><cell>58 (54.2)</cell><cell>63 (61.2)</cell><cell></cell></row><row><cell>Predominantly inattentive</cell><cell>36 (35.0)</cell><cell>44 (41.5)</cell><cell>43 (40.2)</cell><cell>34 (33.0)</cell><cell></cell></row><row><cell>Predominantly hyperactive-impulsive</cell><cell>2 (1.9)</cell><cell>8 (7.5)</cell><cell>6 (5.6)</cell><cell>6 (5.8)</cell><cell></cell></row><row><cell>Current comorbid Axis I disorders d</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>≥1 Current clinical disorder</cell><cell>35 (34.0)</cell><cell>38 (35.8)</cell><cell>38 (35.5)</cell><cell>48 (46.6)</cell><cell>Abbreviations: ADHD,</cell></row><row><cell>Affective disorders</cell><cell>24 (23.3)</cell><cell>23 (21.7)</cell><cell>23 (21.5)</cell><cell>36 (35.0)</cell><cell>attention-deficit/hyperactivity</cell></row><row><cell>Anxiety disorders</cell><cell>17 (16.5)</cell><cell>19 (17.9)</cell><cell>20 (18.7)</cell><cell>21 (20.4)</cell><cell>disorder; CM, clinical management;</cell></row><row><cell>Other disorders Current comorbid Axis II disorders d</cell><cell>3 (2.9)</cell><cell>5 (4.7)</cell><cell>2 (1.9)</cell><cell>6 (5.8)</cell><cell>GPT, group psychotherapy; NOS, not otherwise specified; WURS-k, Wender Utah Rating Scale (in</cell></row><row><cell>≥1 Current personality disorder</cell><cell>22 (21.4)</cell><cell>17 (16.0)</cell><cell>16 (15.0)</cell><cell>20 (19.4)</cell><cell>German).</cell></row><row><cell>Cluster A, schizoid, paranoid</cell><cell>1 (1.0)</cell><cell>0</cell><cell>0</cell><cell>4 (3.9)</cell><cell>a Verbal IQ was estimated as 23 in 1</cell></row><row><cell>Cluster B, borderline, narcissistic, histrionic</cell><cell>4 (3.9)</cell><cell>4 (3.8)</cell><cell>7 (6.5)</cell><cell>4 (3.9)</cell><cell>patient for whom German was not</cell></row><row><cell>Cluster C, avoidant, obsessive-compulsive, dependent</cell><cell>18 (17.5)</cell><cell>11 (10.4)</cell><cell>10 (9.3)</cell><cell>13 (12.6)</cell><cell>the native language. b Including patients also engaged in</cell></row><row><cell>Other, depressive, negativistic, NOS</cell><cell>3 (2.9)</cell><cell>4 (3.8)</cell><cell>4 (3.7)</cell><cell>4 (3.9)</cell><cell>training, retraining, university</cell></row><row><cell>Comorbid Axis I disorders in remission d</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>studies, and professional education (GPT with methylphenidate, n = 3;</cell></row><row><cell>≥1 Clinical disorder in remission</cell><cell>44 (42.7)</cell><cell>60 (56.6)</cell><cell>52 (48.6)</cell><cell>39 (37.9)</cell><cell>GPT with placebo, n = 6; CM with</cell></row><row><cell>Affective disorders</cell><cell>28 (27.2)</cell><cell>31 (29.2)</cell><cell>32 (29.9)</cell><cell>22 (21.4)</cell><cell>methylphenidate, n = 2; and CM</cell></row><row><cell>Anxiety disorders</cell><cell>6 (5.8)</cell><cell>8 (7.5)</cell><cell>10 (9.3)</cell><cell>8 (7.8)</cell><cell>with placebo, n = 1).</cell></row><row><cell>Substance abuse or dependence</cell><cell>14 (13.6)</cell><cell>30 (28.3)</cell><cell>22 (20.6)</cell><cell>11 (10.7)</cell><cell></cell></row><row><cell>Other disorders</cell><cell>11 (10.7)</cell><cell>9 (8.5)</cell><cell>6 (5.6)</cell><cell>11 (10.7)</cell><cell></cell></row></table><note><p><s>c Sample size was 102.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>and Observer-Rated CAARS ADHD Index at Baseline (T1), 13 Weeks (T2), 26 Weeks (T3), and 52 Weeks (T4) Based on Last Mean Carried Forward Analysis for the 419 Participants in the Full Analysis Set by Randomized Intervention, Adjusted for Baseline Measurement and Center</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell>T2 − T1,</cell><cell></cell><cell>T3 − T1,</cell><cell></cell><cell>T4 − T1,</cell></row><row><cell>Observer-Rated CAARS Score a</cell><cell>T1, Mean</cell><cell>T2, Mean (95% CI)</cell><cell>Mean</cell><cell>T3, Mean (95% CI)</cell><cell>Mean</cell><cell>T4, Mean (95% CI)</cell><cell>Mean</cell></row><row><cell>ADHD Index b</cell><cell>20.6</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>GPT with methylphenidate</cell><cell></cell><cell>16.7 (15.6 to 17.8)</cell><cell>−3.8</cell><cell>15.4 (14.3 to 16.5)</cell><cell>−5.1</cell><cell>14.9 (13.6 to 16.1)</cell><cell>−5.7</cell></row><row><cell>GPT with placebo</cell><cell></cell><cell>18.4 (17.2 to 19.5)</cell><cell>−2.2</cell><cell>17.6 (16.4 to 18.8)</cell><cell>−3.0</cell><cell>16.4 (15.2 to 17.6)</cell><cell>−4.2</cell></row><row><cell>CM with methylphenidate</cell><cell></cell><cell>15.6 (14.5 to 16.7)</cell><cell>−5.0</cell><cell>14.6 (13.4 to 15.7)</cell><cell>−6.0</cell><cell>14.6 (13.4 to 15.8)</cell><cell>−6.0</cell></row><row><cell>CM with placebo</cell><cell></cell><cell>17.3 (16.2 to 18.5)</cell><cell>−3.2</cell><cell>17.4 (16.2 to 18.6)</cell><cell>−3.2</cell><cell>17.5 (16.1 to 18.8)</cell><cell>−3.1</cell></row><row><cell>Difference, GPT − CM</cell><cell></cell><cell>1.1 (0.0 to 2.2)</cell><cell></cell><cell>0.5 (0.6 to 1.7)</cell><cell></cell><cell>−0.4 (−1.6 to 0.8)</cell><cell></cell></row><row><cell>P value</cell><cell></cell><cell>.06</cell><cell></cell><cell>.36</cell><cell></cell><cell>.53</cell><cell></cell></row><row><cell>Difference,</cell><cell></cell><cell>−1.7 (−2.8 to −0.6)</cell><cell></cell><cell>−2.5 (−3.7 to −1.3)</cell><cell></cell><cell>−2.2 (−3.5 to −1.0)</cell><cell></cell></row><row><cell>methylphenidate − placebo</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>P value</cell><cell></cell><cell>.003</cell><cell></cell><cell>&lt;.001</cell><cell></cell><cell>&lt;.001</cell><cell></cell></row><row><cell>Inattention/memory problems c</cell><cell>20.8</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>GTP with methylphenidate</cell><cell></cell><cell>17.1 (15.9 to 18.3)</cell><cell>−3.7</cell><cell>16.1 (14.9 to 17.4)</cell><cell>−4.7</cell><cell>15.0 (13.8 to 16.3)</cell><cell>−5.8</cell></row><row><cell>GPT with placebo</cell><cell></cell><cell>18.0 (16.8 to 19.2)</cell><cell>−2.8</cell><cell>17.4 (16.1 to 18.7)</cell><cell>−3.5</cell><cell>16.0 (14.7 to 17.4)</cell><cell>−4.8</cell></row><row><cell>CM with methylphenidate</cell><cell></cell><cell>15.7 (14.5 to 16.8)</cell><cell>−5.2</cell><cell>14.9 (13.6 to 16.2)</cell><cell>−5.9</cell><cell>15.2 (14.0 to 16.5)</cell><cell>−5.6</cell></row><row><cell>CM with placebo</cell><cell></cell><cell>17.8 (16.5 to 19.0)</cell><cell>−3.1</cell><cell>17.8 (16.4 to 19.2)</cell><cell>−3.0</cell><cell>17.5 (16.1 to 19.0)</cell><cell>−3.3</cell></row><row><cell>Difference, GPT − CM</cell><cell></cell><cell>0.8 (−0.4 to 2.0)</cell><cell></cell><cell>0.4 (−0.9 to 1.7)</cell><cell></cell><cell>−0.8 (−2.1 to 0.5)</cell><cell></cell></row><row><cell>P value</cell><cell></cell><cell>.18</cell><cell></cell><cell>.56</cell><cell></cell><cell>.21</cell><cell></cell></row><row><cell>Difference,</cell><cell></cell><cell>−1.5 (−2.7 to −0.3)</cell><cell></cell><cell>−2.1 (−3.4 to −0.8)</cell><cell></cell><cell>−1.7 (−3.0 to −0.3)</cell><cell></cell></row><row><cell>methylphenidate − placebo</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>P value</cell><cell></cell><cell>.01</cell><cell></cell><cell>.001</cell><cell></cell><cell>.02</cell><cell></cell></row><row><cell>Hyperactivity/restlessness c</cell><cell>18.3</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>GPT with methylphenidate</cell><cell></cell><cell>14.8 (13.6 to 15.9)</cell><cell>−3.5</cell><cell>13.6 (12.4 to 14.8)</cell><cell>−4.7</cell><cell>13.0 (11.8 to 14.3)</cell><cell>−5.2</cell></row><row><cell>GPT with placebo</cell><cell></cell><cell>15.8 (14.5 to 17.0)</cell><cell>−2.5</cell><cell>15.0 (13.7 to 16.2)</cell><cell>−3.3</cell><cell>14.9 (13.5 to 16.3)</cell><cell>−3.4</cell></row><row><cell>CM with methylphenidate</cell><cell></cell><cell>14.5 (13.4 to 15.6)</cell><cell>−3.8</cell><cell>13.4 (12.2 to 14.7)</cell><cell>−4.8</cell><cell>13.3 (12.1 to 14.5)</cell><cell>−5.0</cell></row><row><cell>CM with placebo</cell><cell></cell><cell>15.2 (13.9 to 16.4)</cell><cell>−3.1</cell><cell>15.2 (13.9 to 16.5)</cell><cell>−3.1</cell><cell>15.2 (13.8 to 16.5)</cell><cell>−3.1</cell></row><row><cell>Difference, GPT − CM</cell><cell></cell><cell>0.4 (0.7 to 1.6)</cell><cell></cell><cell>−0.1 (−1.3 to 1.2)</cell><cell></cell><cell>−0.3 (−1.6 to 1.0)</cell><cell></cell></row><row><cell>P value</cell><cell></cell><cell>.47</cell><cell></cell><cell>.92</cell><cell></cell><cell>.68</cell><cell></cell></row><row><cell>Difference,</cell><cell></cell><cell>−0.9 (−2.0 to 0.3)</cell><cell></cell><cell>−1.6 (−2.8 to −0.4)</cell><cell></cell><cell>−1.9 (−3.2 to −0.6)</cell><cell></cell></row><row><cell>methylphenidate − placebo</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>P value</cell><cell></cell><cell>.15</cell><cell></cell><cell>.01</cell><cell></cell><cell>.005</cell><cell></cell></row><row><cell cols="2">Impulsivity and emotional lability c 18.6</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>GPT with methylphenidate</cell><cell></cell><cell>15.7 (14.6 to 16.9)</cell><cell>−2.8</cell><cell>14.0 (12.7 to 15.3)</cell><cell>−4.6</cell><cell>13.6 (12.4 to 14.9)</cell><cell>−4.9</cell></row><row><cell>GPT with placebo</cell><cell></cell><cell>16.0 (14.8 to 17.2)</cell><cell>−2.6</cell><cell>15.9 (14.5 to 17.2)</cell><cell>−2.7</cell><cell>14.3 (13.0 to 15.6)</cell><cell>−4.3</cell></row><row><cell>CM with methylphenidate</cell><cell></cell><cell>13.7 (12.5 to 14.8)</cell><cell>−4.9</cell><cell>13.5 (12.2 to 14.8)</cell><cell>−5.1</cell><cell>13.7 (12.5 to 14.9)</cell><cell>−4.9</cell></row><row><cell>CM with placebo</cell><cell></cell><cell>15.3 (14.1 to 16.4)</cell><cell>−3.3</cell><cell>15.5 (14.0 to 16.9)</cell><cell>−3.1</cell><cell>15.7 (14.4 to 17.0)</cell><cell>−2.8</cell></row><row><cell>Difference, GPT − CM</cell><cell></cell><cell>1.4 (0.2 to 2.6)</cell><cell></cell><cell>0.5 (−0.9 to 1.8)</cell><cell></cell><cell>−0.8 (−2.0 to 0.5)</cell><cell></cell></row><row><cell>P value</cell><cell></cell><cell>.02</cell><cell></cell><cell>.50</cell><cell></cell><cell>.23</cell><cell></cell></row><row><cell>Difference,</cell><cell></cell><cell>−0.9 (−2.1 to 0.2)</cell><cell></cell><cell>−2.0 (−3.3 to −0.6)</cell><cell></cell><cell>−1.3 (−2.6 to −0.1)</cell><cell></cell></row><row><cell>methylphenidate − placebo</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>P value</cell><cell></cell><cell>.12</cell><cell></cell><cell>.004</cell><cell></cell><cell>.04</cell><cell></cell></row><row><cell>Problems with self-concept d</cell><cell>9.9</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>GPT with methylphenidate</cell><cell></cell><cell>8.7 (8.0 to 9.4)</cell><cell>−1.2</cell><cell>8.2 (7.4 to 8.9)</cell><cell>−1.7</cell><cell>7.7 (6.9 to 8.5)</cell><cell>−2.2</cell></row><row><cell>GPT with placebo</cell><cell></cell><cell>9.2 (8.5 to 9.9)</cell><cell>−0.7</cell><cell>9.0 (8.3 to 9.8)</cell><cell>−0.8</cell><cell>8.4 (7.5 to 9.2)</cell><cell>−1.5</cell></row><row><cell>CM with methylphenidate</cell><cell></cell><cell>8.3 (7.6 to 8.9)</cell><cell>−1.6</cell><cell>7.9 (7.1 to 8.7)</cell><cell>−2.0</cell><cell>7.9 (7.1 to 8.7)</cell><cell>−1.9</cell></row><row><cell>CM with placebo</cell><cell></cell><cell>9.0 (8.3 to 9.7)</cell><cell>−0.9</cell><cell>8.8 (8.0 to 9.5)</cell><cell>−1.1</cell><cell>8.7 (7.8 to 9.6)</cell><cell>−1.2</cell></row><row><cell>Difference, GPT − CM</cell><cell></cell><cell>0.3 (−0.4 to 1.0)</cell><cell></cell><cell>0.3 (−0.5 to 1.1)</cell><cell></cell><cell>−0.3 (−1.1 to 0.5)</cell><cell></cell></row><row><cell>P value</cell><cell></cell><cell>.41</cell><cell></cell><cell>.49</cell><cell></cell><cell>.49</cell><cell></cell></row><row><cell>Difference,</cell><cell></cell><cell>−0.6 (−1.3 to 0.1)</cell><cell></cell><cell>−0.9 (−1.6 to −0.1)</cell><cell></cell><cell>−0.7 (−1.5 to 0.1)</cell><cell></cell></row><row><cell>methylphenidate − placebo</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>P value</cell><cell></cell><cell>.08</cell><cell></cell><cell>.03</cell><cell></cell><cell>.09</cell><cell></cell></row></table><note><p><s>Abbreviations: ADHD, attention-deficit/hyperactivity disorder; CAARS, Conners Adult ADHD Rating Scale, long version; CM, clinical management; GPT, group psychotherapy.</s><s>a Lower score values represent better outcomes.</s><s>b Possible range is 0 to 36.</s><s>Primary outcome was at T2. c Possible range is 0 to 36.</s><s>d Possible range is 0 to 18.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>Observer-Rated CAARS ADHD Index at Baseline (T1), 13 Weeks (T2), 26 Weeks (T3), and 52 Weeks (T4) With Logistic Regression of Complete Cases by Randomized Intervention, Adjusted for Baseline Measurement and Center</s></p></div></figDesc><table><row><cell cols="7">Observer-Rated CAARS Score Response a T2</cell><cell></cell><cell></cell><cell>T3</cell><cell></cell><cell></cell><cell>T4</cell><cell></cell><cell></cell><cell></cell><cell cols="5">Abbreviations: ADHD, attention-deficit/hyperactivity</cell></row><row><cell cols="5">Patients with response, No./total</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="5">disorder; CAARS, Conners Adult</cell></row><row><cell cols="3">patients, No. (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="6">ADHD Rating Scale, long version; CM,</cell></row><row><cell></cell><cell cols="4">GPT with methylphenidate</cell><cell></cell><cell cols="2">27/91 (29.7)</cell><cell></cell><cell cols="2">38/82 (46.3)</cell><cell></cell><cell cols="3">35/69 (50.7)</cell><cell></cell><cell cols="5">clinical management; GPT, group</cell></row><row><cell></cell><cell cols="2">GPT with placebo</cell><cell></cell><cell></cell><cell></cell><cell cols="2">21/86 (24.4)</cell><cell></cell><cell cols="2">25/75 (33.3)</cell><cell></cell><cell cols="3">26/59 (44.1)</cell><cell></cell><cell cols="5">psychotherapy; OR, odds ratio.</cell></row><row><cell></cell><cell cols="3">CM with methylphenidate</cell><cell></cell><cell></cell><cell cols="2">45/95 (47.4)</cell><cell></cell><cell cols="2">50/85 (58.8)</cell><cell></cell><cell cols="3">37/70 (52.9)</cell><cell></cell><cell cols="5">a Decrease in ADHD Index score by 30% or more compared with T1.</cell></row><row><cell cols="4">CM with placebo GPT vs CM, OR (95% CI) b</cell><cell></cell><cell></cell><cell cols="3">26/80 (32.5) 0.55 (0.35 to 0.86)</cell><cell cols="3">21/62 (33.9) 0.71 (0.44 to 1.12)</cell><cell cols="4">21/45 (46.7) 0.91 (0.54 to 1.53)</cell><cell cols="5">b The ORs are from the logistic regression of complete cases</cell></row><row><cell></cell><cell>P value</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">.009</cell><cell></cell><cell>.14</cell><cell></cell><cell></cell><cell></cell><cell>.72</cell><cell></cell><cell></cell><cell cols="5">without missing data, adjusted for</cell></row><row><cell cols="6">Methylphenidate vs placebo, OR (95% CI) b P value</cell><cell cols="3">1.57 (1.00 to 2.47) .05</cell><cell cols="3">2.17 (1.35 to 3.50) .001</cell><cell cols="4">1.19 (0.70 to 2.01) .52</cell><cell cols="6">the baseline ADHD Index and center. An OR &gt; 1.00 indicates higher odds for a better outcome for the first vs second intervention.</cell></row><row><cell cols="19">Figure 2. Mean Attention-Deficit/Hyperactivity Disorder (ADHD) Index Scores by Randomized Intervention for the 419 Participants</cell><cell></cell><cell></cell></row><row><cell cols="4">in the Full Analysis Set</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="5">Group psychotherapy with methylphenidate</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="4">Group psychotherapy with placebo</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="5">Clinical management with methylphenidate</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="4">Clinical management with placebo</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">Treatment combinations</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>22</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>22</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>22</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>ADHD Index Score</cell><cell>20 18 16 14</cell><cell></cell><cell></cell><cell cols="3">Group psychotherapy Clinical management</cell><cell>ADHD Index Score</cell><cell>20 18 16 14</cell><cell></cell><cell></cell><cell cols="3">Methylphenidate Placebo</cell><cell>ADHD Index Score</cell><cell>20 18 16 14</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>12</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>12</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>12</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>0</cell><cell>10</cell><cell>20</cell><cell>30</cell><cell>40</cell><cell>50</cell><cell>60</cell><cell>0</cell><cell>10</cell><cell>20</cell><cell>30</cell><cell>40</cell><cell>50</cell><cell>60</cell><cell>0</cell><cell>10</cell><cell>20</cell><cell>30</cell><cell>40</cell><cell>50</cell><cell>60</cell></row><row><cell></cell><cell></cell><cell></cell><cell cols="2">Time, wk</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">Time, wk</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">Time, wk</cell><cell></cell><cell></cell></row></table><note><p><s>CMethylphenidate and placeboBGroup psychotherapy and clinical managementA Means (last mean carried forward) for the primary outcome measure, observer-rated Conners Adult ADHD Rating Scale ADHD Index, for group psychotherapy and clinical management (A), methylphenidate and placebo (B), and group psychotherapy with methylphenidate, group psychotherapy with placebo, clinical management with methylphenidate, and clinical management with placebo.</s><s>Error bars indicate 95% CIs.</s><s>Treatment Efficacy for Adult Attention-Deficit/Hyperactivity Disorder Original Investigation Research jamapsychiatry.com</s><s>(Reprinted) JAMA Psychiatry December 2015 Volume 72, Number 12</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 5 .</head><label>5</label><figDesc><div><p><s>Observer-Rated CGI at Baseline (T1), 13 Weeks (T2), 26 Weeks (T3), and 52 Weeks (T4) Based on Cumulative Logistic Regression of Complete Cases With No Missing Values for the 419 Participants in the Full Analysis Set by Randomized Intervention, Adjusted for Baseline Severity of Illness and Center a</s></p></div></figDesc><table><row><cell cols="3">Treatment Efficacy for Adult Attention-Deficit/Hyperactivity Disorder</cell><cell></cell><cell></cell><cell>Original Investigation Research</cell></row><row><cell>Observer-Rated CGI Score</cell><cell>T1</cell><cell>T2</cell><cell>T3</cell><cell>T4</cell></row><row><cell>Severity b</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean (No.) c</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>GPT with methylphenidate</cell><cell>4.7 (103)</cell><cell>4.0 (89)</cell><cell>3.7 (81)</cell><cell>3.4 (69)</cell></row><row><cell>GPT with placebo</cell><cell>4.6 (104)</cell><cell>4.2 (84)</cell><cell>4.0 (74)</cell><cell>3.6 (57)</cell></row><row><cell>CM with methylphenidate</cell><cell>4.7 (106)</cell><cell>4.0 (93)</cell><cell>3.8 (84)</cell><cell>3.7 (67)</cell></row><row><cell>CM with placebo</cell><cell>4.7 (101)</cell><cell>4.2 (79)</cell><cell>4.0 (61)</cell><cell>3.7 (45)</cell></row><row><cell>GPT vs CM, OR (95% CI) d</cell><cell></cell><cell>0.94 (0.64 to 1.39)</cell><cell>1.03 (0.68 to 1.56)</cell><cell>0.75 (0.47 to 1.20)</cell></row><row><cell>P value</cell><cell></cell><cell>.76</cell><cell>.87</cell><cell>.23</cell></row><row><cell>Methylphenidate vs placebo, OR (95% CI) d P value</cell><cell></cell><cell>0.63 (0.43 to 0.94) .02</cell><cell>0.59 (0.39 to 0.90) .01</cell><cell>0.71 (0.45 to 1.14) .16</cell><cell>Abbreviations: CGI, Clinical Global Impression Scale; CM, clinical management; GPT, group</cell></row><row><cell>Global change e</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>psychotherapy; NA, not applicable;</cell></row><row><cell>Mean (No.) c</cell><cell>NA</cell><cell></cell><cell></cell><cell></cell><cell>OR, odds ratio.</cell></row><row><cell>GPT with methylphenidate</cell><cell></cell><cell>2.9 (91)</cell><cell>2.7 (82)</cell><cell>2.5 (69)</cell><cell>a Lower score values represent better outcomes except for the CGI global</cell></row><row><cell>GPT with placebo</cell><cell></cell><cell>3.0 (84)</cell><cell>3.0 (74)</cell><cell>2.7 (58)</cell><cell>assessment of effectiveness.</cell></row><row><cell>CM with methylphenidate</cell><cell></cell><cell>3.0 (94)</cell><cell>2.9 (84)</cell><cell>2.9 (67)</cell><cell>b Possible scores range from 1 (not at</cell></row><row><cell>CM with placebo</cell><cell></cell><cell>3.2 (79)</cell><cell>3.2 (61)</cell><cell>3.0 (45)</cell><cell>all ill) to 7 (extremely ill).</cell></row><row><cell>GPT vs CM, OR (95% CI) d</cell><cell></cell><cell>0.71 (0.48 to 1.05)</cell><cell>0.74 (0.48 to 1.13)</cell><cell>0.62 (0.38 to 0.99)</cell><cell>c Descriptive numerical evaluation.</cell></row><row><cell>P value</cell><cell></cell><cell>.08</cell><cell>.16</cell><cell>.047</cell><cell>d The ORs are from cumulative</cell></row><row><cell>Methylphenidate vs placebo, OR (95% CI) d P value</cell><cell></cell><cell>0.69 (0.47 to 1.02) .07</cell><cell>0.56 (0.36 to 0.86) .008</cell><cell>0.69 (0.43 to 1.12) .13</cell><cell>logistic regression of complete cases, adjusted for baseline CGI severity of illness subscale score and center. An OR &lt; 1.00 indicates</cell></row><row><cell>Global assessment of effectiveness f</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>higher odds for a better outcome for the first vs second intervention.</cell></row><row><cell>Mean (No.) c</cell><cell>NA</cell><cell></cell><cell></cell><cell></cell><cell>e Possible scores range from 1 (very</cell></row><row><cell>GPT with methylphenidate</cell><cell></cell><cell>2.5 (91)</cell><cell>2.7 (82)</cell><cell>2.9 (69)</cell><cell>much improved) to 7 (very much</cell></row><row><cell>GPT with placebo</cell><cell></cell><cell>2.3 (84)</cell><cell>2.4 (74)</cell><cell>2.7 (58)</cell><cell>worse).</cell></row><row><cell>CM with methylphenidate</cell><cell></cell><cell>2.2 (94)</cell><cell>2.3 (83)</cell><cell>2.5 (67)</cell><cell>f Possible scores range from 1 (minimal) to 4 (very good).</cell></row><row><cell>CM with placebo GPT vs CM, OR (95% CI) g</cell><cell></cell><cell>1.8 (79) 2.22 (1.50 to 3.28)</cell><cell>2.0 (61) 1.99 (1.30 to 3.04)</cell><cell>2.0 (45) 2.72 (1.67 to 4.45)</cell><cell>g The ORs are from cumulative logistic regression of complete</cell></row><row><cell>P value</cell><cell></cell><cell>&lt;.001</cell><cell>.001</cell><cell>&lt;.001</cell><cell>cases, adjusted for baseline CGI</cell></row><row><cell>Methylphenidate vs placebo, OR (95% CI) g P value</cell><cell></cell><cell>1.77 (1.20 to 2.61) .004</cell><cell>1.86 (1.22 to 2.84) .004</cell><cell>1.80 (1.11 to 2.91) .02</cell><cell>severity of illness subscale score and center. An OR &gt; 1.00 indicates higher odds for a better outcome for the first vs second intervention.</cell></row></table><note><p><s>jamapsychiatry.com</s><s>(Reprinted) JAMA Psychiatry December 2015 Volume 72, Number 12</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">d In some patients, more than 1 disorder was diagnosed.</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">JAMA Psychiatry December 2015 Volume 72, Number 12 (Reprinted) jamapsychiatry.com Copyright 2015 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 05/17/2022</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Copyright 2015 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 05/17/2022</note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Author Contributions: Drs Philipsen and Graf had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</s><s>Drs Berger and Tebartz van Elst contributed equally.</s><s>Study concept and design: Philipsen, Jans, Graf, Alm, Retz, Ihorst, Schlander, Berger, Tebartz van Elst.</s><s>Acquisition, analysis, or interpretation of data: Philipsen, Jans, Graf, Matthies, Borel, Colla, Gentschow, Langner, Jacob, Groß-Lesch, Sobanski, Schumacher-Stien, Roesler, Retz, Retz-Junginger, Kis, Abdel-Hamid, Heinrich, Huss, Kornmann, Bürger, Perlov, Schlander, Berger, Tebartz van Elst.</s><s>Drafting of the manuscript: Philipsen, Graf, Colla, Retz, Heinrich, Tebartz van Elst.</s><s>Critical revision of the manuscript for important intellectual content: Philipsen, Jans, Graf, Matthies, Borel, Colla, Gentschow, Langner, Jacob, Groß-Lesch, Sobanski, Alm, Schumacher-Stien, Roesler, Retz-Junginger, Kis, Abdel-Hamid,</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Clinical practice: adult attention deficit-hyperactivity disorder</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">D</forename><surname>Volkow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Swanson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">369</biblScope>
			<biblScope unit="issue">20</biblScope>
			<biblScope unit="page" from="1935" to="1944" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder</title>
		<author>
			<persName><forename type="first">J</forename><surname>Fayyad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Graaf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kessler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">190</biblScope>
			<biblScope unit="page" from="402" to="409" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title level="m" type="main">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders</title>
		<imprint>
			<publisher>American Psychiatric Association</publisher>
			<pubPlace>Washington, DC</pubPlace>
		</imprint>
	</monogr>
	<note>5th ed.</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Impact of comorbidity in adults with attention-deficit/hyperactivity disorder</title>
		<author>
			<persName><forename type="first">J</forename><surname>Biederman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychiatry</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="3" to="7" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Adult psychiatric status of hyperactive boys grown up</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mannuzza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bessler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Malloy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lapadula</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">155</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="493" to="498" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">A clinical perspective of attention-deficit/hyperactivity disorder into adulthood</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Wilens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Dodson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychiatry</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1301" to="1313" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Cost of illness and comorbidities in adults diagnosed with attention-deficit/hyperactivity disorder: a retrospective analysis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Hodgkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Montejano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sasané</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Huse</surname></persName>
		</author>
		<idno>PCC.10m01030</idno>
	</analytic>
	<monogr>
		<title level="j">Prim Care Companion CNS Disord</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">2</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Systematic review of national and international guidelines on attention-deficit hyperactivity disorder</title>
		<author>
			<persName><forename type="first">M</forename><surname>Seixas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Weiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Müller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Psychopharmacol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="753" to="765" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<author>
			<persName><forename type="first">D</forename><surname>Ebert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Krause</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Roth-Sackenheim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">ADHD in adulthood: guidelines based on expert consensus with DGPPN support</title>
				<imprint>
			<date type="published" when="2003">2003</date>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="939" to="946" />
		</imprint>
	</monogr>
	<note>in German</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Canadian Attention Deficit Hyperactivity Disorder Resource Alliance. Canadian ADHD Practice Guidelines</title>
	</analytic>
	<monogr>
		<title level="j">Canadian Attention Deficit Hyperactivity Disorder Resource Alliance</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder</title>
		<author>
			<persName><forename type="first">M</forename><surname>Koesters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Becker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kilian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Fegert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Weinmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Psychopharmacol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="733" to="744" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">V</forename><surname>Faraone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Spencer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Aleardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pagano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Biederman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychopharmacol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="24" to="29" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Hazell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Kohn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Dickson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Walton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Granger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Wyk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Atten Disord</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="674" to="683" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Safren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Otto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sprich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Winett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Wilens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Biederman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Behav Res Ther</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="831" to="842" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Cognitive behaviour therapy in medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial</title>
		<author>
			<persName><forename type="first">B</forename><surname>Emilsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Gudjonsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Sigurdsson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Psychiatry</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">116</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Practitioner review: non-pharmacological treatments for ADHD: a lifespan approach</title>
		<author>
			<persName><forename type="first">S</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Amarasinghe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Child Psychol Psychiatry</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="116" to="133" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Cognitive behavior therapy for adults with attention-deficit/ hyperactivity disorder: a review of recent randomized controlled trials</title>
		<author>
			<persName><forename type="first">M</forename><surname>Mongia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hechtman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Psychiatry Rep</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="561" to="567" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Psychotherapy in adult attention deficit hyperactivity disorder: implications for treatment and research</title>
		<author>
			<persName><forename type="first">A</forename><surname>Philipsen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Rev Neurother</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1217" to="1225" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Evaluation of the efficacy and effectiveness of a structured disorder tailored psychotherapy in ADHD in adults: study protocol of a randomized controlled multicentre trial</title>
		<author>
			<persName><forename type="first">A</forename><surname>Philipsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Graf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Tebartz</forename><surname>Van Elst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Atten Defic Hyperact Disord</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="203" to="212" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Psychotherapy of attention deficit hyperactivity disorder in adults: a pilot study using a structured skills training program</title>
		<author>
			<persName><forename type="first">B</forename><surname>Hesslinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Tebartz</forename><surname>Van Elst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Nyberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Arch Psychiatry Clin Neurosci</title>
		<imprint>
			<biblScope unit="volume">252</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="177" to="184" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Reduced ADHD symptoms in adults with ADHD after structured skills training group: results from a randomized controlled trial</title>
		<author>
			<persName><forename type="first">T</forename><surname>Hirvikoski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Waaler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Alfredsson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Behav Res Ther</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="175" to="185" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Structured group psychotherapy in adults with attention deficit hyperactivity disorder: results of an open multicentre study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Philipsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Richter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Peters</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Nerv Ment Dis</title>
		<imprint>
			<biblScope unit="volume">195</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1013" to="1019" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Safren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sprich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Mimiaga</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial</title>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">304</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="875" to="880" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Efficacy of meta-cognitive therapy for adult ADHD</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Solanto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Marks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wasserstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">167</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="958" to="968" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">National Collaborating Centre for Mental Health. Attention Deficit Hyperactivity Disorder: Diagnosis and Management of ADHD in Children, Young People and Adults</title>
		<author>
			<persName><forename type="first">M</forename><surname>Weiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Murray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wasdell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Greenfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Giles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hechtman</surname></persName>
		</author>
		<idno>12:30. 28</idno>
	</analytic>
	<monogr>
		<title level="j">BMC Psychiatry</title>
		<imprint>
			<date type="published" when="2009">2012. 2009</date>
			<publisher>British Psychological Society</publisher>
		</imprint>
	</monogr>
	<note>A randomized controlled trial of CBT therapy for adults with ADHD with and without medication</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Clinical Global Impression Scale</title>
		<author>
			<persName><forename type="first">W</forename><surname>Guy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">ECDEU Assessment Manual for Psychopharmacology-Revised</title>
		<editor>Guy W</editor>
		<imprint>
			<biblScope unit="volume">1976</biblScope>
			<biblScope unit="page" from="218" to="222" />
		</imprint>
		<respStmt>
			<orgName>US Department of Health, Education &amp; Welfare</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">A randomized controlled multicenter trial on the multimodal treatment of adult attention-deficit hyperactivity disorder: enrollment and characteristics of the study sample</title>
		<author>
			<persName><forename type="first">A</forename><surname>Philipsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Graf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Jans</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Atten Defic Hyperact Disord</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="35" to="47" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<monogr>
		<title level="m" type="main">Wender Utah Rating Scale: the short version for the assessment of the attention-deficit hyperactivity disorder in adults</title>
		<author>
			<persName><forename type="first">P</forename><surname>Retz-Junginger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Retz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Blocher</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>in German</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Nervenarzt</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="830" to="838" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<monogr>
		<title level="m" type="main">Reliability and validity of the Wender-Utah Rating Scale short form: retrospective assessment of symptoms for attention deficit/hyperactivity disorder</title>
		<author>
			<persName><forename type="first">P</forename><surname>Retz-Junginger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Retz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Blocher</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>in German</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Nervenarzt</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="987" to="993" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<monogr>
		<title level="m" type="main">Tools for the diagnosis of attention-deficit/hyperactivity disorder in adults: self-rating behaviour questionnaire and diagnostic checklist</title>
		<author>
			<persName><forename type="first">M</forename><surname>Rösler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Retz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Retz-Junginger</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>in German</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title/>
		<idno type="DOI">10.1007/s00115-003-1622-2</idno>
		<idno>doi:10.1007 /s00115-003-1622-2</idno>
	</analytic>
	<monogr>
		<title level="j">Nervenarzt</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="888" to="895" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<monogr>
		<author>
			<persName><forename type="first">T</forename><surname>Fydrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Renneberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Schmitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">U</forename><surname>Wittchen</surname></persName>
		</author>
		<author>
			<persName><surname>Skid-Ii</surname></persName>
		</author>
		<title level="m">Strukturiertes Klinisches Interview Für DSM-IV, Achse II: Persönlichkeitsstörungen: Interviewheft. Göttingen, Germany: Hogrefe; 1997. 35. Wittchen HU, Wunderlich U, Gruschwitz S, Zaudig M. SKID-I: Strukturiertes Klinisches Interview Für DSM-IV, Achse I: Psychische Störungen: Interviewheft</title>
				<meeting><address><addrLine>Göttingen, Germany</addrLine></address></meeting>
		<imprint>
			<publisher>Hogrefe</publisher>
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<monogr>
		<title level="m" type="main">Adult ADHD Rating Scales (CAARS). Toronto, ON: Multi-Health Systems</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Conners</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Erhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sparrow</surname></persName>
		</author>
		<author>
			<persName><surname>Conners</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">German validation of the Conners Adult ADHD Rating Scales-self-report (CAARS-S) I: factor structure and normative data</title>
		<author>
			<persName><forename type="first">H</forename><surname>Christiansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Hirsch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Psychiatry</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="100" to="107" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">German validation of the Conners Adult ADHD Rating Scale-self-report: confirmation of factor structure in a large sample of participants with ADHD</title>
		<author>
			<persName><forename type="first">H</forename><surname>Christiansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Hirsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Philipsen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Atten Disord</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="690" to="698" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Philipsen A. Differential diagnosis and comorbidity of attention-deficit/hyperactivity disorder (ADHD) and borderline personality disorder (BPD) in adults</title>
		<author>
			<persName><forename type="first">H</forename><surname>Christiansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Hirsch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Arch Psychiatry Clin Neurosci</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="42" to="46" />
			<date type="published" when="2006">2012. 2006</date>
		</imprint>
	</monogr>
	<note>Eur Psychiatry. suppl</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">B</forename><surname>Hesslinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Philipsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Richter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychotherapie Der ADHS im Erwachsenenalter: Ein Arbeitsbuch</title>
		<imprint>
			<date type="published" when="2004">2004</date>
			<publisher>Hogrefe</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<monogr>
		<title level="m" type="main">Beck Depression Inventory</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Beck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Steer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Brown</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1996">1996</date>
			<publisher>Psychological Corp</publisher>
			<pubPlace>San Antonio, TX</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<monogr>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">Y</forename><surname>Herzberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Goldschmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Heinrichs</surname></persName>
		</author>
		<title level="m">Beck Depressions-Inventar (BDI-II): revision. Rep Psychologie</title>
				<imprint>
			<date type="published" when="2008">2008</date>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="301" to="302" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Analysis of longitudinal trials with protocol deviation: a framework for relevant, accessible assumptions, and inference via multiple imputation</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Carpenter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Roger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Kenward</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biopharm Stat</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1352" to="1371" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Kessler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Adler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Barkley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">163</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="716" to="723" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Representativeness of participants in a clinical trial for attention-deficit/hyperactivity disorder? comparison with adults from a large observational study</title>
		<author>
			<persName><forename type="first">Cbh</forename><surname>Surman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Monuteaux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Petty</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychiatry</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1612" to="1616" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Drug combinations in the treatment of refractory depression: a review</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Stern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mendels</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychiatry</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="368" to="373" />
			<date type="published" when="1981">1981</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder</title>
		<author>
			<persName><forename type="first">T</forename><surname>Spencer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Biederman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Wilens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol Psychiatry</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="456" to="463" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Psychostimulants in moderate to severe affective disorder: a systematic review of randomized controlled trials</title>
		<author>
			<persName><forename type="first">L</forename><surname>Abbasowa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">V</forename><surname>Kessing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vinberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nord J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="369" to="382" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder</title>
		<author>
			<persName><surname>Mta Cooperative Group</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Gen Psychiatry</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1073" to="1086" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Review of medication adherence in children and adults with ADHD</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">D</forename><surname>Adler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Nierenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Postgrad Med</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="184" to="191" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Huss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ginsberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tvedten</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial</title>
	</analytic>
	<monogr>
		<title level="j">Adv Ther</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="44" to="65" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
